author-photo

Monique Dail

Genentech

25

Papers

209

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

Venetoclax in Combination with Gilteritinib Demonstrates Molecular Clearance of FLT3 mutation in Relapsed/Refractory FLT3 -Mutated Acute Myeloid Leukemia

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
A Novel Transcriptomic Classifier for AML Is Highly Associated with Drug Sensitivity

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax Combined with Hypomethylating Agents

2021 Blood
Show All
- Source
- Cite
- Save
Citations (0)
Assessment of Minimal Residual Disease By Next-Generation Sequencing and Fluorodeoxyglucose-Positron Emission Tomography in Patients with Relapsed/Refractory Multiple Myeloma Treated with Venetoclax in Combination with Carfilzomib and Dexamethasone

2020 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Loss of glucocorticoid receptor expression mediates in vivo dexamethasone resistance in T-cell acute lymphoblastic leukemia

2020 Leukemia
Show All
- Source
- Cite
- Save
Citations (13)
Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models.

2020 Haematologica
Show All
- Source
- Cite
- Save
Citations (22)
Updated Results from the Venetoclax (Ven) in Combination with Idasanutlin (Idasa) Arm of a Phase 1b Trial in Elderly Patients (Pts) with Relapsed or Refractory (R/R) AML Ineligible for Cytotoxic Chemotherapy

2019 Blood
Show All
- Source
- Cite
- Save
Citations (16)
Convergent genetic aberrations in murine and human T lineage acute lymphoblastic leukemias

2019 PLOS Genetics
Show All
- Source
- Cite
- Save
Citations (3)
Cytogenetic and Molecular Drivers of Outcome with Venetoclax-Based Combination Therapies in Treatment-Naïve Elderly Patients with Acute Myeloid Leukemia (AML)

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (2)
Safety, Efficacy, Pharmacokinetic (PK) and Biomarker Analyses of BCL2 Inhibitor Venetoclax (Ven) Plus MDM2 Inhibitor Idasanutlin (idasa) in Patients (pts) with Relapsed or Refractory (R/R) AML: A Phase Ib, Non-Randomized, Open-Label Study

2018 Blood
Show All
- Source
- Cite
- Save
Citations (18)